Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Performer
6098.0000 -42.00 (-0.68%)
NSE Jan 20, 2026 11:58 AM
Volume: 98,489
 

6098.00
-0.68%
Motilal Oswal
Gross margin improved ~210bp YoY (~130bp QoQ) to 62.5%. This, along with a decline in other expenditure by ~180bp (as % of sales), led to margin expansion by ~180bp YoY to 35.5%. EBITDA rose ~8% YoY (+19% QoQ) to INR3.9b (est. PAT, however, grew by just 26 May 2018 ~1% YoY to INR2.6b, mainly due to a higher tax of 34% v/s 26% in 4QFY17. For FY18, sales, EBITDA and PAT stood at INR39b (-4.
Divi's Laboratories .. has an average target of 6270.00 from 6 brokers.
More from Divi's Laboratories Ltd.
Recommended